Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: A meta-analysis of randomized controlled trials

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 4751-4760

  Chen, Jian ^a   Lu, Yingfeng ^a   Zheng, Yunliang ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Bevacizumab; Hypertension; Meta analysis; Non small cell lung cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; DULANERMIN; ERLOTINIB; GEMCITABINE; IXABEPILONE; PACLITAXEL; PEMETREXED; ANGIOGENESIS INHIBITOR;

ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SAFETY; DRUG USE; HUMAN; HYPERTENSION; INCIDENCE; META ANALYSIS; NON SMALL CELL LUNG CANCER; PATIENT MONITORING; PATIENT RISK; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; BLOOD PRESSURE; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; DRUG EFFECTS; LUNG NEOPLASMS; ODDS RATIO; PATHOLOGY; PATHOPHYSIOLOGY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; BLOOD PRESSURE; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; HYPERTENSION; INCIDENCE; LUNG NEOPLASMS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84939809036     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S87258     Document Type: Article

References (46)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
2. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26(28):4617–4625.
3. Stinchcombe TE, Socinski MA. Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc. 2009;6(2):233–241.
4. Francis H, Solomon B. The current status of targeted therapy for non-small cell lung cancer. Intern Med J. 2010;40(9):611–618.
5. Parums DV. Current status of targeted therapy in non-small cell lung cancer. Drugs Today (Barc). 2014;50(7):503–525.
6. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med. 1998;49:407–424.
7. Chiappori AA, Kolevska T, Spigel DR, et al. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. Ann Oncol. 2015;26(2):354–362.
8. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184–2191.
9. Herbst RS, Ansari R, Bustin F, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011;377(9780):1846–1854.
10. Su Y, Yang WB, Li S, Ye ZJ, Shi HZ, Zhou Q. Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PloS One. 2012;7(4):e35629.
11. Niho S, Kunitoh H, Nokihara H, et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer. 2012;76(3):362–367.
12. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27(8):1227–1234.
13. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
14. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23(9):1351–1375.
15. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28(2):123–137.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
17. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101.
18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
19. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–2550.
20. Herbst RS, O’Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol. 2007;25(30):4743–4750.
21. Soria JC, Márk Z, Zatloukal P, et al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol. 2011;29(33):4442–4451.
22. Spigel DR, Greco FA, Waterhouse DM, et al. Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer. Lung Cancer. 2012;78(1):70–75.
23. Boutsikou E, Kontakiotis T, Zarogoulidis P, et al. Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer. Onco Targets Ther. 2013;6:125–134.
24. Artal Cortés A, Calera Urquizu L, Hernando Cubero J. Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art. Transl Lung Cancer Res. 2015;4(2):191–197.
25. Petrioli R, Francini E, Fiaschi AI, et al. Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study. Med Oncol. 2015;32(4):134.
26. Tamiya A, Tamiya M, Shiroyama T, et al. Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations. Med Oncol. 2015;32(3):40.
27. Montero JA, Yanez-Castro G, Sanchis-Merino ME, Ruiz-Moreno JM. Bevacizumab in vitreous haemorrhage secondary to radiation retinopathy. BMJ Case Rep. 2014;2014.
28. Fu DB, Alexandru D, Curticiu DM, Fu Y, Bota DA. Two patients with brain tumors who received bevacizumab and radiotherapy: optic neuropathy and quality-of-life issues. J Adv Pract Oncol. 2013;4(4):252–256.
29. Hong S, Tan M, Wang S, Luo S, Chen Y, Zhang L. Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2015;141(5):909–921.
30. Pereg D, Lishner M. Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword? Eur Heart J. 2008;29(19):2325–2326.
31. Kaidar-Person O, Badarna H, Bar-Sela G. Bevacizumab for metastatic colon cancer: does patient BMI influence survival? Anticancer Drugs. 2015;26(3):363–366.
32. Hamdollah Zadeh MA, Amin EM, Hoareau-Aveilla C, et al. Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance. Mol Oncol. 2015;9(1):167–178.
33. Robinson ES, Khankin EV, Choueiri TK, et al. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension. 2010;56(6):1131–1136.
34. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111(5):707–716.
35. Lambrechts D, Claes B, Delmar P, et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol. 2012;13(7):724–733.
36. Yu J, Cao XF, Zheng Y, et al. Anti-VEGF therapy with bevacizumab – limited cardiovascular toxicity. Asian Pac J Cancer Prev. 2014;15(24):10769–10772.
37. Garcia-Donas J, Esteban E, Leandro-García LJ, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011;12(12):1143–1150.
38. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011;123(21):2434–2506.
39. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of hypertension. 2009;27(11):2121–2158.
40. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20(5):807–815.
41. Sato Y, Sonoda H. The vasohibin family: a negative regulatory system of angiogenesis genetically programmed in endothelial cells. Arterioscler Thromb Vasc Biol. 2007;27(1):37–41.
42. Runge Sørensen C, Madsen JK, Schmidt F, Sloth E. [No evidence for renal protective effect of loop diuretics for patients having oliguria.]Ugeskr Laeger. 2012;174(43):2617–2620. Danish.
43. Jaeschke R, Gajewski P, Brozek J. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2002;106(5):e18.
44. Dhurandhar EJ, Kaiser KA, Dawson JA, Alcorn AS, Keating KD, Allison DB. Predicting adult weight change in the real world: a systematic review and meta-analysis accounting for compensatory changes in energy intake or expenditure. Int J Obes (Lond). Epub 2014 Oct 17.
45. Sedgwick P. Meta-analyses: what is heterogeneity? BMJ. 2015;350:h1435.
46. Zhang Z, Xu X, Ni H. Small studies may overestimate the effect sizes in critical care meta-analyses: a meta-epidemiological study. Crit Care. 2013;17(1):R2.